Pesquisar
Tivic Health Systems Inc
TIVCAdicionar à lista de desejos
1.400USD
0.0000.00%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.92MValor de mercado
PerdaP/L TTM
Mais detalhes de Tivic Health Systems Inc Empresa
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
Informações de Tivic Health Systems Inc
Código da empresaTIVC
Nome da EmpresaTivic Health Systems Inc
Data de listagemNov 11, 2021
CEOErnst (Jennifer)
Número de funcionários7
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 11
Endereço47685 Lakeview Blvd
CidadeFREMONT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94538
Telefone18882766888
Sitehttps://tivichealth.com/
Código da empresaTIVC
Data de listagemNov 11, 2021
CEOErnst (Jennifer)
Executivos da empresa Tivic Health Systems Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+28.89%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
10.00K
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+28.89%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
10.00K
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 7 de mai
Atualizado em: qui, 7 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Avenue Capital Group
3.24%
Geode Capital Management, L.L.C.
2.81%
Sanctuary Advisors, LLC
1.95%
Marex Group plc
1.89%
3I Management LLC
1.50%
Outro
88.62%
Investidores
Investidores
Proporção
Avenue Capital Group
3.24%
Geode Capital Management, L.L.C.
2.81%
Sanctuary Advisors, LLC
1.95%
Marex Group plc
1.89%
3I Management LLC
1.50%
Outro
88.62%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
7.54%
Investment Advisor
3.80%
Individual Investor
2.26%
Research Firm
0.16%
Hedge Fund
0.05%
Outro
86.19%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
23
362.58K
11.55%
+205.09K
2025Q4
22
224.75K
8.90%
+144.85K
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Avenue Capital Group
101.64K
3.53%
+101.64K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
7.73K
0.27%
--
--
Jan 31, 2026
Marex Group plc
40.94K
1.42%
+2.55K
+6.64%
Dec 31, 2025
3I Management LLC
47.05K
1.64%
+47.05K
--
Feb 21, 2026
Ernst (Jennifer)
32.69K
1.14%
+9.44K
+40.62%
Dec 26, 2025
Susquehanna International Group, LLP
14.64K
0.51%
+14.64K
--
Dec 31, 2025
Handley Michael K
8.82K
0.31%
+8.82K
--
Feb 18, 2026
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Data
Data ex-dividendo
Tipo
Proporção
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
